This Biopharma Stock Could More than Double on Oral Eczema Treatment, Goldman Sachs Says

Why It Matters

An effective oral eczema therapy could capture a sizable share of a rapidly expanding market, dramatically boosting Corvus’s valuation and offering investors outsized upside.

Key Takeaways

• Goldman Sachs sets $40 target, 166% upside for Corvus.
• Oral drug soquelitinib shows 75% response in early trial.
• Atopic dermatitis market projected >$24B by 2035.
• Corvus shares up 9% after coverage, 113% YTD gain.
• All seven analysts rate buy or strong‑buy.

Pulse Analysis

The atopic dermatitis (AD) landscape is undergoing a shift as patients and payers seek alternatives to injectable biologics. Current therapies often require frequent dosing and carry steroid‑related side effects, creating a sizable unmet need for convenient, long‑acting oral options. Market analysts forecast the AD treatment market to surpass $24 billion by 2035, driven by rising prevalence of moderate‑to‑severe cases and heightened awareness of skin health. This macro backdrop sets the stage for innovators that can deliver efficacy with a simpler administration route.

Corvus Pharmaceuticals’ lead candidate, soquelitinib (CPI‑818), is a non‑steroidal oral molecule designed to modulate key inflammatory pathways implicated in eczema. In a Phase 1/2 study, 75% of participants experienced meaningful improvement, a signal that positions the drug favorably against a crowded pipeline of topical and injectable competitors. The oral formulation promises dosing convenience and potentially longer intervals between administrations, attributes that could translate into higher adherence and lower overall treatment costs—critical factors for both clinicians and insurers.

From an investment perspective, Goldman Sachs’ initiation of coverage and a $40 price target signal confidence that Corvus is undervalued relative to its growth prospects. The firm’s 166% upside projection aligns with a broader analyst consensus, with all seven covering houses rating the stock as buy or strong‑buy. While the upside is compelling, investors should weigh execution risk, including later‑stage trial outcomes and regulatory timelines. Nonetheless, a successful launch of soquelitinib could catapult Corvus into a leadership position within the emerging oral AD segment, delivering substantial returns for shareholders.